Amgen (AMGN): FY25 Q1 earnings call, May 1, 2025

Thu, May 1Earnings callSpeaker-labelled transcriptAmgen

No Kalshi or Polymarket word markets were listed for Amgen’s May 1, 2025 earnings call (FY25 Q1). The transcript is searchable below (quotes of at most 25 words).

Updated

Transcript

quotes of at most 25 words

Speaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.

3 matches for “Tavneos”; 3 quoted, at least 25 words apart.

Robertcompanyprepared

…to rare disease. Our four key growth drivers: TEPEZZA, KRYSTEXXA, UPLIZNA and TAVNEOS, are all early in their life cycles and well positioned for long-term…

Bradwaycompanyprepared

…to rare disease. Our four key growth drivers: TEPEZZA, KRYSTEXXA, UPLIZNA and TAVNEOS, are all early in their life cycles and well positioned for long-term…

Murdo Gordoncompanyqa

…that these drugs treat -- and whether it's TEPEZZA, UPLIZNA, KRYSTEXXA or TAVNEOS, these are going to be key growth driving products for us over…

Agents: this page as TSV at /api/v1/appearances/amgen:2025-05-01:earnings_call · words: /api/v1/brief?appearance=amgen:2025-05-01:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP